Based on the above results, GCN5 aggravated the severity of cardiac hypertrophy under the presence of TAC or PE treatment, while GCN5 overexpression alone was not sufficient to initiate or promote cardiac hypertrophy. Here, KAT2B is linked to cardiac hypertrophy.